Kathryn F. Mileham

Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham et al. · JAMA Oncology · 2018 · 673 citations · Full text

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee et al. · Annals of Oncology · 2021 · 273 citations · Full text

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey

David Waterhouse, R. Donald Harvey, Patricia A. Hurley et al. · JCO Oncology Practice · 2020 · 194 citations

Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules

Gerard A. Silvestri, Nichole T. Tanner, Paul Kearney et al. · CHEST Journal · 2018 · 159 citations · Full text